Boardroom drama: a look at hostile bids, backstabbing and pharma coups d'etat

3 May 2017

In the midst of a comprehensive cost cutting program rumored to include thousands of job losses, Teva Pharmaceutical Industries' (NYSE: TEVA) chief financial officer Eyal Desheh is about to quit, Israeli press reports.

Mr Desheh would be the latest in a spate of executive departures at the embattled drugmaker, after generics chief executive Siggi Olafsson abruptly downed tools in December, and CEO Erez Vigodman elected not to continue in post earlier this year.

Managerial turbulence at Teva is not confined to the recent past. At times, the company’s boardroom has appeared to host more drama than an episode of The Apprentice.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK